OmniComm Systems, Inc. Responds To Industry's Growing Demand For Integrated Electronic Data Capture (EDC) Solutions And Signs 15 New Deals In Second Quarter 2007

A Mix Of New And Existing Companies Choose TrialMaster^TM Over Other EDC Vendors For Their Clinical Trials

FT. LAUDERDALE, FL - July 23, 2007 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they have closed 15 new business deals in Q2, 2007. Key market segments for the new business include pharmaceutical, medical device, contract research organizations (CRO) and academic medical center customers, including a high profile Top 50 pharmaceutical company. TrialMaster will be implemented in both an ASP, fully hosted environment for the new trials and also in 2 new Technology Transfer deployments for those clients that want to bring EDC in-house.

OmniComm's Sr. Vice President of Business Development, Stephen Johnson, commented, "The company's escalating growth is a direct result of the drug development industry's need for flexible and integrated solutions for clinical trials. TrialMaster provides sponsors with a feature rich EDC product that is easy to use, easy to integrate with and is not laden with hidden or exorbitant costs." Added Johnson, "Our Support and Consulting Services groups are made up of industry veterans that stand ready to deliver quality driven solutions and support for our customers using EDC."

2007 business deals include:

• 16 month, Phase II, Infectious Disease study with 11 sites and 45 subjects
• 18 month, Phase IIb, Analgesia study with 10 sites and 100 subjects
• 21 month, Phase II-III, Analgesia study with 10 sites and 100 subjects
• 21 month, Phase II-III, Analgesia study with 10 sites and 100 subjects

• 36 month, Phase IV, Cardiovascular study with 12 sites and 200 subjects
• 36 month, Phase III Pivotal Cardiovascular study with 30 sites and 150 subjects
• 36 month, Phase III Pivotal Cardiovascular study with 20 sites and 175 subjects
• 36 month, Phase III Pivotal Cardiovascular study with 25 sites and 150 subjects

• 13 month, Phase II, Oncology study with 8 sites and 40 subjects
• 3 month, Phase I, Bioequivalence study with 1 site and 20 subjects
• 3 month, Phase I, Bioequivalence study with 1 site and 18 subjects
• 36 month, Phase II, Oncology study with 45 sites and 160 subjects followed by a Technology Transfer
• 24 month, Phase III, Dermatology study with 70 sites and 800 subjects
• 24 month, Phase III, Dermatology study with 70 sites and 800 subjects

• 2 NCI-funded Oncology trials followed by a Technology Transfer

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled "The Promise of Next-Gen eClinical Trial Software" by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Back